Norspan (Buprenorphine)

Buprenorphine, the active ingredient in Norspan, is an opioid partial agonist presented as a 5 µg/h, 10 µg/h, 15 µg/h, or 20 µg/h transdermal patch for transdermal use. It provides continuous analgesia for chronic severe pain and cancer‑related pain in patients requiring ongoing opioid therapy. The patch delivers medication steadily over several days, allowing stable plasma concentrations.

GNH USA supplies Norspan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets.

Buprenorphine, administered via transdermal delivery, is indicated for the following pain conditions: - Chronic severe pain: provides continuous opioid analgesia for patients with persistent severe pain unresponsive to non‑opioid treatments. - Cancer‑related pain: offers stable pain control for malignant disease‑associated pain requiring around‑the‑clock opioid therapy. - Severe musculoskeletal pain: delivers ongoing analgesia for advanced osteoarthritis or similar conditions when other therapies are insufficient.

Common Side Effects: - Application site erythema or irritation. - Nausea or vomiting. - Constipation. - Dizziness or headache.

Serious or Rare Side Effects: - Respiratory depression, especially in opioid‑naïve patients. - Severe hypotension or adrenal insufficiency. - Opioid withdrawal syndrome if the patch is removed abruptly. - Severe skin reactions such as Stevens‑Johnson syndrome.

Before initiating therapy, evaluate opioid tolerance and respiratory status. - Assess opioid tolerance: confirm patient is opioid‑experienced to reduce risk of severe respiratory depression. - Monitor for respiratory depression: especially during the first 24 hours and after dose adjustments. - Avoid use in severe respiratory disease: patients with COPD, sleep apnea, or other compromised ventilation. - Caution with CNS depressants: dose may need reduction when combined with benzodiazepines, alcohol, or similar agents. - Store at room temperature: keep patches in the original pouch, protect from light and moisture.

Major Interactions (Avoid): - Concomitant full opioid agonists: additive risk of respiratory depression. - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase buprenorphine plasma concentrations.

Moderate Interactions (Monitor Closely): - Central nervous system depressants (benzodiazepines, barbiturates, alcohol): may enhance sedation and respiratory effects. - CYP3A4 inducers (rifampin, carbamazepine, phenytoin): may reduce buprenorphine efficacy. - QT‑prolonging drugs: may increase the risk of cardiac arrhythmias.